Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Neutrophil extracellular traps contribute to coagulopathy after traumatic brain injury
Jiaqi Jin, Fang Wang, Jiawei Tian, Xinyi Zhao, Jiawei Dong, Nan Wang, Zhihui Liu, Hongtao Zhao, Wenqiang Li, Ge Mang, Shaoshan Hu
Jiaqi Jin, Fang Wang, Jiawei Tian, Xinyi Zhao, Jiawei Dong, Nan Wang, Zhihui Liu, Hongtao Zhao, Wenqiang Li, Ge Mang, Shaoshan Hu
View: Text | PDF
Research Article Cell biology Neuroscience

Neutrophil extracellular traps contribute to coagulopathy after traumatic brain injury

  • Text
  • PDF
Abstract

Coagulopathy contributes to the majority of deaths and disabilities associated with traumatic brain injury (TBI). Whether neutrophil extracellular traps (NETs) contribute to an abnormal coagulation state in the acute phase of TBI remains unknown. Our objectives were to demonstrate the definitive role of NETs in coagulopathy in TBI. We detected NET markers in 128 TBI patients and 34 healthy individuals. Neutrophil-platelet aggregates were detected in blood samples from TBI patients and healthy individuals using flow cytometry and staining for CD41 and CD66b. Endothelial cells were incubated with isolated NETs and we detected the expression of vascular endothelial cadherin, syndecan-1, thrombomodulin, von Willebrand factor, phosphatidylserine, and tissue factor. In addition, we established a TBI mouse model to determine the potential role of NETs in TBI-associated coagulopathy. NET generation was mediated by high mobility group box 1 (HMGB1) from activated platelets and contributed to procoagulant activity in TBI. Furthermore, coculture experiments indicated that NETs damaged the endothelial barrier and caused these cells to assume a procoagulant phenotype. Moreover, the administration of DNase I before or after brain trauma markedly reduced coagulopathy and improved the survival and clinical outcome of mice with TBI.

Authors

Jiaqi Jin, Fang Wang, Jiawei Tian, Xinyi Zhao, Jiawei Dong, Nan Wang, Zhihui Liu, Hongtao Zhao, Wenqiang Li, Ge Mang, Shaoshan Hu

×

Figure 7

DNase I as therapeutic in TBI-associated coagulopathy.

Options: View larger image (or click on image) Download as PowerPoint
DNase I as therapeutic in TBI-associated coagulopathy.
To evaluate the p...
To evaluate the potential of DNase I as a therapeutic target, we established a TBI mouse model. Plasma levels of citH3-DNA (A), fibrinogen (B), and D-dimer (C) in sham (n = 9), TBI + saline (n = 9), and TBI + DNase I (n = 9) mice. (D) Levels (OD unit) of Evans blue in the supernatants of tissue homogenates from mice in each group (n = 9). Plasma levels of citH3-DNA (E) and levels (OD unit) of Evans blue (F) between mice preconditioned with DNase I (a) and those that received DNase I after injury (b). (G) Modified Neurological Severity Score (mNSS) (n = 9) of sham, TBI + saline, and TBI + DNase I mice. (H) Kaplan-Meier survival analysis of sham, TBI + saline, and TBI + DNase I mice. *P < 0.05 versus TBI + saline mice. Data are presented as the mean ± SD. *P < 0.05; **P < 0.01; ****P < 0.0001 by 2-way ANOVA with Tukey’s multiple-comparison test (A–C and G) or 1-way ANOVA with Tukey’s multiple-comparison test (D–F).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts